Journey Medical (DERM) Gains from Sales and Divestitures (2021 - 2025)
Historic Gains from Sales and Divestitures for Journey Medical (DERM) over the last 5 years, with Q3 2025 value amounting to $927446.0.
- Journey Medical's Gains from Sales and Divestitures rose 375.27% to $927446.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $927446.0, marking a year-over-year increase of 375.27%. This contributed to the annual value of $1.1 million for FY2024, which is 4553.12% up from last year.
- According to the latest figures from Q3 2025, Journey Medical's Gains from Sales and Divestitures is $927446.0, which was up 375.27% from $324159.0 recorded in Q2 2025.
- Over the past 5 years, Journey Medical's Gains from Sales and Divestitures peaked at $1.1 million during Q4 2024, and registered a low of $2000.0 during Q1 2022.
- In the last 5 years, Journey Medical's Gains from Sales and Divestitures had a median value of $287951.0 in 2022 and averaged $395161.2.
- As far as peak fluctuations go, Journey Medical's Gains from Sales and Divestitures skyrocketed by 333310.0% in 2023, and later plummeted by 7610.7% in 2025.
- Journey Medical's Gains from Sales and Divestitures (Quarter) stood at $136500.0 in 2021, then skyrocketed by 115.17% to $293707.0 in 2022, then soared by 147.61% to $727249.0 in 2023, then surged by 45.53% to $1.1 million in 2024, then decreased by 12.37% to $927446.0 in 2025.
- Its Gains from Sales and Divestitures stands at $927446.0 for Q3 2025, versus $324159.0 for Q2 2025 and $50421.0 for Q1 2025.